Publications by authors named "M Van Moffaert"
Article Synopsis
- * Most patients (76.0%) were moderately to extremely ill at the start, but after 3-6 weeks of treatment with an average dose of 175 mg/day, many showed significant improvements in their symptoms and overall health ratings.
- * Sulpiride was generally well tolerated with low rates of severe side effects, as only 1.2% of patients dropped out due to adverse events, and the medication's efficacy and acceptance were consistent across different countries.
Consultation-Liaison psychiatric service delivery: results from a European study.
Gen Hosp Psychiatry
September 2001
The reported findings of the European Consultation-Liaison Workgroup (ECLW) Collaborative Study describe consultation-liaison service delivery by 56 services from 11 European countries aggregated on a C-L service level. During the period of 1 year (1991), the participants applied a standardized, reliability tested method of patient data collection, and data were collected describing pertinent characteristics of the hospital, the C-L service, and the participating consultants. The consultation rate of 1% (median; 1.
View Article and Find Full Text PDFThe authors identified variations in the characteristics of patients referred to 56 consultation-liaison (C-L) services in 11 European countries. The authors found differences in the types of patients referred to the services, and there were significant differences between countries. The first difference lays in whether services saw patients for deliberate self-harm and for substance abuse.
View Article and Find Full Text PDFEuropean Consultation-Liaison Psychiatric Services: the ECLW Collaborative Study.
Acta Psychiatr Scand
May 2000
Objective: To describe the patterns of organization of consultation-liaison (C-L) services in 11 European countries in relation to hospital characteristics and national approaches to C-L psychiatry.
Method: Cross-sectional survey.
Results: Services can best be described in terms of their size and seniority of their staff and whether or not they are multidisciplinary.
Objective: To compare the efficacy and tolerability of mirtazapine and fluoxetine in depressed inpatients and outpatients.
Method: Patients with a major depressive episode (DSM-III-R), a baseline score of > or=21 on the 17-item Hamilton Rating Scale for Depression (HAM-D), and > or=2 on HAM-D Item 1 (depressed mood) were randomly assigned to a 6-week treatment with either mirtazapine (N=66, 15-60 mg/day) or fluoxetine (N=67, 20-40 mg/day). The upper limit of the mirtazapine dose range was above the dose range approved in the United States (15-45 mg/day).